Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2010
04/13/2010US7696244 2-(2-Chloro-benzoylamino)-4,5,6,7-tetrahydro-benzo thiophene-3-carboxylic acid amide; increasing activity of mutant-cystic fibrosis transmembrane conductance regulator protein in a cell; increasing halide ion permeability of a cell producing a Delta F508-CFTR protein
04/13/2010US7696243 Pyrrolidin-2-one derivatives for use as DP1 receptor agonists
04/13/2010US7696242 inhibitors of the hepatitis C virus NS3 protease; azalactone intermediate reacted with cycloalkylsulfonamide and decylization; urea or carbamate-terminated alkylglycine, hydroxyproline, cyclopropylglycine tripeptide
04/13/2010US7696241 sarcopenia,frailty or age-related functional decline; nonsteroidal, nontoxic; side effect reduction;2-Chloro-4-(-4-hydroxy-1-oxo-hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-3-methylbenzonitrile
04/13/2010US7696240 3-Methyl-1-naphthalen-1-ylmethyl-1H-indole-2-carboxylic acid; inhibit chymase; allergic, inflammatory and/or fibrotic diseases, such as allergy, asthma, peripheral arterial occlusive disease
04/13/2010US7696239 Tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators
04/13/2010US7696238 Substituted benzo[d]isoxazol-3-yl amine compounds as analgesics
04/13/2010US7696236 Method of providing pirfenidone therapy to a patient
04/13/2010US7696235 3-{[(4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid; post-surgical and post-laser trabeculectomy ocular hypertensive episodes, presurgical adjuncts
04/13/2010US7696234 Histamine H3 receptor agents, preparation and therapeutic uses
04/13/2010US7696231 Therapy, prevention of metabolism disorders; insulin resistance; antidiabetic agents; hypoglycemic agents; anticholesterol agents; obesity; polycystic ovarian syndrome
04/13/2010US7696230 1-(aminomethyl)cyclohexan acetic acid 2-methoxy-4-[(1E)-3-[4-(nitrooxy) butoxy]-3-oxy-1-propenyl]phenyl hydrochloride ester ; reduced side effects; neuropathic pain
04/13/2010US7696229 Compounds having 5-HT6 receptor affinity
04/13/2010US7696228 Oral preparation of dyclonine hydrochloride
04/13/2010US7696227 Small-molecule inhibitors of the androgen receptor
04/13/2010US7696226 HIV protease inhibiting compounds
04/13/2010US7696225 (2-carboxamido)(3-Amino) thiophene compounds
04/13/2010US7696224 Phenylurea derivatives as inhibitors of tyrosine kinases for the treatment of tumour diseases
04/13/2010US7696223 Pyrrolo- and Thiazolo-pyridine compounds, and methods of use thereof
04/13/2010US7696222 Indole derivatives as CRTH2 receptor antagonists
04/13/2010US7696221 Thienoisoquinoline-phenylsulfonamides and their use as ER-NFκB inhibitors
04/13/2010US7696220 Methods for the treatment or inhibition of ileus
04/13/2010US7696219 administering composition comprising vitamin C, vitamin E, the B-complex vitamins, chromium, selenium, and zinc; can be used by patients afflicted with renal disease, renal insufficiency, or end-stage renal disease
04/13/2010US7696218 6-(2-Fluoro-4-iodophenylamino)-N-methoxy-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; 5-Acetyl-6-(2-fluoro-4-iodophenylamino)-1,3-dimethylpyrimidine-2,4(- 1H,3H)-dione; hyperproliferative disorders
04/13/2010US7696217 N-(pyridin-2-ylmethyl)-4-methyl-3-oxo-4-aza-5 alpha -androst-1-en-17 beta -acetamide; enhancement of weakened muscle tone; osteoporosis, bone disorders; ; periodontal disease, frailty, aging skin, male hypogonadism, postmenopausal symptoms, inflammatory arthritis, cachexia, Alzheimer's disease
04/13/2010US7696216 Aryl-quinazoline/aryl-2-amino-phenyl methanone derivatives
04/13/2010US7696215 N-isoxazol-3-yl-4-methyl-3-[6-(4-methylpiperazin-1-yl)-4-oxoquinazolin-3(4H)-yl]benzamide; rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, inflammatory bowel disease, multiple sclerosis, AIDS, septic shock, congestive heart failure, ischaemic heart disease or psoriasis
04/13/2010US7696214 Confining solid tumors; administering a tyrosine kinase inhibitor as antitumor agents; 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline
04/13/2010US7696213 2-amino-8-(trans-4-hydroxycyclohexyl)-4-methyl-7-oxo-N-1H-pyrazol-5-yl-7,8-dihydropyrido[2,3-d]pyrimidine-6-carboxamide; anticarcinogenic; phosphoinositide 3-kinase alpha (PI3-K alpha ) inhibitor; cell cycle regulation, proliferation, apoptosis; inhibit resistance to cytotoxic agents in cancer cells
04/13/2010US7696212 1-[(phenanthridin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine; antiarthritic agents; obesity; antidiabetic agents; osteoporosis; dipeptidylpeptidase-IV (DPP-IV) inhibitors
04/13/2010US7696211 administering an A1 adenosine receptor antagonist in combination with an antibiotic agent
04/13/2010US7696210 Gonadotropin releasing hormone receptor antagonists
04/13/2010US7696209 1(R)-1-(4-methyl-2-oxo-2,3-dihydro-benzoxazol-6-ylmethyl)-2-oxo-2-[4-(tetrahydropyran-4-yl)-piperazin-1-yl]-ethyl 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl); calcitonin gene related peptide antagonist; analgesic, antidiabetic agent; migraine or cluster headaches, non-insulin-dependent diabetes
04/13/2010US7696208 4-(2-Pyridyl)-1-amino(thio)carbonylpiperazine derivatives are inhibitors of VR1 expression in a cell
04/13/2010US7696207 Therapeutic agents useful for treating pain
04/13/2010US7696206 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
04/13/2010US7696205 Cyclic amide derivative as monocyte chemotactic protein modulator; prevention and treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma; antiinflammatory agents; 4-Methylsulfanyl-N-{2-[2-(4-trifluoromethyl-1H-benzoimidazol-2-yl)-acetylamino]-cyclohexyl}-benzamide
04/13/2010US7696204 Pharmaceutical compounds
04/13/2010US7696203 3-amino-N-[4-(2-morpholin-4-yl-1-benzopyran-4-one)-dibenzofuran-1-yl]-propionamides ; anticancer, antitumor agents
04/13/2010US7696202 IL-12 modulatory compounds
04/13/2010US7696201 e.g. ethyl-4-((2-oxo-1,2-dihydrospiro[benzo[d]1,3]oxazine-4,4'-piperidine]-1'-yl)methyl)piperidine-1-carboxylate; central nervous system disorders; natidepressant, cognition activator, neurodegenerative diseases; obesity, Alzheimer's disease, psychosis, schizophrenia, mania, bipolar disorders
04/13/2010US7696200 4-{[4-(5-Chloro-2-methoxy-benzenesulfonyl)-3,4-dihydro-2H-benzo[1,4]oxazine-6-carbonyl]-amino}-benzoic acid; Type II diabetes; carnitine-dependent palmitoyltransferases (CPTs)
04/13/2010US7696199 Pyrazole compounds effective and selective toward the sigma receptors, e.g., 4-{2-(1-(3,4-dichlorophenyl)-5-methyl-1H pyrazol-3-yloxy)ethyl}morpholine; treatment of pain, more preferably neuropathic pain or allodynia; psychosis; neurodenerative disorders; antiinflammatory and - arthritic agents; obesity
04/13/2010US7696198 Phosphodiesterase 4 inhibitors
04/13/2010US7696197 having a calpain inhibiting activity and an activity which traps the reactive oxygen species (ROS); for protecting acoustic hair cells;
04/13/2010US7696196 (R)-1-(3,4-dibromo-benzyl)-2-[4-(1-methyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate, for example; treatment of headaches, particularly migraine or cluster headaches
04/13/2010US7696195 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
04/13/2010US7696194 Visual function disorder improving agents
04/13/2010US7696193 Such as 6-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxy)-N-methyl-nicotinamide; for treatment of neurological and psychiatric disorders
04/13/2010US7696192 Tricyclic anilide spirolactam CGRP receptor antagonists
04/13/2010US7696191 Crystalline compound
04/13/2010US7696190 16Alpha-methyl or ethyl substituted estrogens
04/13/2010US7696189 ene steroids as anticarcinogenic agent
04/13/2010US7696188 7,8 and 9-substituted tetracycline compounds
04/13/2010US7696187 Methods of preparing substituted tetracyclines with transition metal-based chemistries
04/13/2010US7696186 7,9-substituted tetracycline compounds
04/13/2010US7696185 Peptidomimetic inhibitors of PSMA, compounds comprising them, and methods of use
04/13/2010US7696184 Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator
04/13/2010US7696183 Prepared by dissolving ibandronate sodium in an aqueous medium, adding propylene glycol, isolating the resulting solvate by filtration; non-hygroscopic, free-flowing, and is chemically and polymorphically stable
04/13/2010US7696182 flushing the catheter for reducing infection and blood flow reduction in blood catheters; contains taurolidine and citric acid or/and lactic acid; prevent clotting in hemodialysis catheters
04/13/2010US7696181 Partial and full agonists of A1 adenosine receptors
04/13/2010US7696180 Antisense oligonucleotide derivative as antitumor agent; biodrugs
04/13/2010US7696178 additive-free, isotonic inhalant of pH 4.0 to 5.5; improved shelf-life at room temperature; acute and chronic endobronchial infections; cystic fibrosis
04/13/2010US7696177 N-[3-(4-{(2S,3R)-2-(-(4-{[(2S, 5S, 3R, 4R, 6R)-3,4,5-trihydroxy-6-(hydroxymethyl)perhydro-2H-pyran-2-yl]ethyl-2-yl}phenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-1-yl}phenyl)propyl]-N-methylmethanesulfonamide; anticholesterol agent; low density lipoprotein; treating atherosclerosis
04/13/2010US7696174 Antimicrobial protein cecropin B, and exhibit cell stimulatory, migratory and antiinflammatory properties; preventing and reversing skin surface damage; wound healing include abrasions, blisters, burns, lacerations, ulcers, bruises, rashes, scars, and the effects of aging
04/13/2010US7696164 Substantially pure glycopeptide antibiotics AC-98-1 ; AC-98-2; AC-98-3; AC-98-4 and AC-98-5
04/13/2010US7696159 Treatment for basal cell carcinoma
04/13/2010US7696151 Providing a screening assay having stearoyl-CoA desaturase biological activity, contacting sceening assay with a test compound and measuring the biological activity
04/13/2010US7696148 An aerosol for the treatment of a microbial infection, comprising a sterile vehicle and a leukotriene dissolved in such vehicle, aerosol comprises a gaseous suspension of fine or liquid particles; treatment and prevention of bacterial pneumonia; pulmonary aerosolization
04/13/2010US7695917 Rescue of gonadotropin releasing hormone receptor mutants
04/13/2010US7695902 Contacting test solution containing Rna and enzyme; hybridization
04/13/2010US7695742 Plant extract mixtures and their uses
04/13/2010US7695740 biomedical materials; synthetic bone; biocompatability
04/13/2010US7695738 Carbohydrate encapsulated nanoparticles
04/13/2010US7695736 Powder of 30-90% a water-soluble cycloxygenase inhibitor, 5-60% of a buffer and 0-10% of other excipients
04/13/2010US7695735 effervescent free; disintegration agent such as croscarmellose, crospovidone; compressible polyol such as mannitol, xylitol; lubricant such as magnesium stearate, sodium stearyl fumarate, stearic acid, micronized polyoxyethylene glycol; sweeteners, flavorings, colors; bioavailability
04/13/2010US7695734 matrix comprising anionic polymer, phosphate buffer; free of pregelatinized starch
04/13/2010US7695732 Nutritional composition for the treatment of pressure ulcers
04/13/2010US7695731 Drug delivery; vascular disease; stents, grafts, anastomotic devices, perivascular wraps, sutures and staples
04/13/2010US7695730 Warming and nonirritating lubricant compositions and method of comparing irritation
04/13/2010US7695729 Nonoral preparation having three-layer structure
04/13/2010US7695722 Methods for reducing GNRH-positive tumor cell replication
04/13/2010US7695426 Methods for enhancing viability
04/13/2010CA2549752C 1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine oxalate (donepezil oxalate) and its polymorphs
04/13/2010CA2537404C Crystalline .gamma.-d form of ivabradine hydrochloride, the process for preparing it, and the pharmaceutical compositions that contain it
04/13/2010CA2506993C Use of docosahexanoic acid as active substance for the treatment of lipodystrophy
04/13/2010CA2486001C Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity
04/13/2010CA2474219C Dihydrobenzodiazepin-2-one derivatives iii
04/13/2010CA2472280C Cytotoxic cyplasin of the sea hare, aplysia punctata, cdna cloning and expression of bioreactive recombinants
04/13/2010CA2465062C Preventive and/or therapeutic agent for viral infection
04/13/2010CA2443802C Pyrazolo[1,5-a]pyridines and medicines containing the same
04/13/2010CA2436220C New mandelic acid derivatives and their use as thrombin inhibitors
04/13/2010CA2435301C Multi-arm block copolymers as drug delivery vehicles
04/13/2010CA2432303C Pyrazole compounds useful as protein kinase inhibitors
04/13/2010CA2432150C Glycosaminoglycans derived from k5 polysaccharide having high antithrombin activity and process for their preparation
04/13/2010CA2431540C Stable skin care compositions containing a retinoid and a retinoid booster system
04/13/2010CA2430363C Compounds and their uses
04/13/2010CA2425440C Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
04/13/2010CA2422377C Pyrazole compounds useful as protein kinase inhibitors
04/13/2010CA2408707C Compositions and methods for the treatment of cancer
1 ... 2312 2313 2314 2315 2316 2317 2318 2319 2320 2321 2322 2323 2324 2325 2326 2327 2328 2329 2330 2331 2332 ... 7860